MONTGOMERY, TEXAS (Business Wire, October 20, 2016) – AngioSoma, Inc. (OTCQB SOAN) is in final negotiations with Dr. Jackie R. See, M.D., F.A.C.C. to join its Scientific Advisory Board. Dr. See was instrumental in the original development of liposomal PGE-1 and is involved in new, and still experimental, uses of PGE-1 and stem cell treatment for the acute stages of peripheral artery disease (‘PAD’) – this opens new and important therapeutic pathways to future Liprostin™ treatments of not only PAD but a wide range of vascular and diabetes-related diseases. Dr. See is a Board Certified Internist, a Fellow of the American College of Cardiology and pioneer of the specialty of Interventional Cardiology (further information on our website at http://angiosoma.com).
“It’s great to be working with Dr. See again, and I believe that his involvement will amplify our ability to broaden Liprostin™ not only in our Phase III trials, but further develop our new patents associated with transdermal skin patches and other methods of treating atherosclerosis,” said Chairman Emeritus Dr. David P. ‘Doc’ Summers, PhD, FACA.
“AngioSoma, Inc. is aggressively adding to its scientific advisory board, expanding its management team, and reviewing intellectual property acquisitions in order to fully develop our product pipeline, thus increasing our shareholder value,” clarified CEO Ms. Alexanderia K Blankenship.
AngioSoma, Inc. has made its September 2016 shareholder presentation available on OTC Markets’ website (http://www.otcmarkets.com/stock/SOAN/video-and-presentations) and an audio interview with Doc Summers will be available on Tuesday at the http://upticknewswire.com website.
ABOUT ANGIOSOMA, INC.
AngioSoma, Inc. (http://www.angiosoma.com) is a clinical stage biopharmaceutical company focused on improving the effectiveness of current standard-of-care treatments, especially related to endovascular interventions in the treatment of peripheral artery disease (‘PAD‘). Our lead pharmaceutical product Liprostin™, a treatment for PAD, has successfully completed FDA Phase I and three Phase II clinical trials, and we are in discussions with several contract research organizations for rapid completion of our U.S. Food and Drug Administration (‘FDA‘) approved protocol for Phase III with submission of our new drug application for marketing in the U.S. and its territories.
NOTICE REGARDING FORWARD LOOKING STATEMENTS
This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including statements that include the words “believes,” “expects,” “anticipate” or similar expressions. Such forward-looking statements involve known and unknown risks, and other factors that may cause the actual results, performance or achievements of the company to differ materially from those expressed or implied by such forward-looking statements. In addition, description of anyone’s past success is no guarantee of future success. This news release speaks as of the date first set forth above and the company assumes no responsibility to update the information included herein for events occurring after the date hereof.